R&D
Precision, speed, impact: Evolving mass spectrometry for med...
MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
News
Amid sector disruption, biotech must focus on 'fundamentals'...
The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.
R&D
Looking to early-stage companies for innovation, with Juerge...
In an interview at BIO 2025, Bayer's Juergen Eckhardt discusses the importance of external innovation and why his company is prioritising early stage.
News
Biogen bids to extend use of Skyclarys to younger patients
Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.
R&D
Going wide on immune system activation, with Jeffrey Meckler
Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
